Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck And Hanmi Partner In First Of A Kind Deal In South Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer
Advertisement

Related Content

Hanmi Sees Double Again: Files For Combination Of Sanofi’s Aprovel And Pfizer’s Lipitor
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
Korea's Hanmi And Merck Move To Sell Hanmi's Hypertension Drug In North America, China and Europe
Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries
Korean Government Fines Five Pharma Multinationals For Unfair Trade
Korean Government Fines Five Pharma Multinationals For Unfair Trade
Advertisement
UsernamePublicRestriction

Register

SC071107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel